In Vivo Models and In Vitro Assays for the Assessment of Pertussis Toxin Activity
Marieke Hoonakker,
Toxins
12th August, 2021
Marieke Hoonakker,
Emerging Microbes & Infections
5th July, 2021
Michiel M Kroes, Alberto Miranda-Bedate, Elise S Hovingh, Ronald Jacobi, Corrie Schot, Elder Pupo, René H M Raeven, Arno A J van der Ark, Jos P M van Putten, Jelle de Wit, Rob Mariman, Elena Pinelli
Scientific Reports
1st July, 2021
Patricia Kaaijk, Maarten E. Emmelot, Hugo D. Meiring, Cécile A. C. M. van Els, Jelle de Wit
Vaccines
25th June, 2021
Patricia Kaaijk, Maarten E. Emmelot, Jeroen Kerkhof, Cécile A.C.M. van Els, Hugo D. Meiring, Jelle de Wit, Rogier Bodewes
Scientific Reports
16th June, 2021
Robin H G A van den Biggelaar , Larissa van der Maas, Hugo D Meiring, Jeroen L A Pennings, Willem van Eden, Victor P M G Rutten, Christine A Jansen
Journal of the American Society of Mass Spectrometry
2nd June, 2021
Thomas J M Michiels, Madelief A van Veen, Hugo D Meiring, Wim Jiskoot, Gideon F A Kersten, Bernard Metz
Vaccine
28th April, 2021
M J Klouwens, M L M Salverda, J J Trentelman, J I Ersoz, A Wagemakers, M J H Gerritzen, P A van der Ley, J W Hovius
Describing the pre-clinical data of the candidate Lyme vaccine based on Intravacc’s OMV platform, this study shows that OMV’s expressing Borrelia (lipo)proteins is a promising vaccine concept that might lead to protecting humans against Lyme disease. Currently, no vaccine against Lyme disease, the fastest growing and most common tick-borne illness in North America and Europe, is available for humans. Antibiotics are the primary treatment and are usually successful, but only when given in time. A vaccine would limit the use of antibiotics and the potential rise of antibiotic resistance. For more information, see also our press release
The Lancet. Infectious Diseases
1st April, 2021
Dani Cohen , Jacob Atsmon, Cécile Artaud, Shiri Meron-Sudai, Marie-Lise Gougeon, Anya Bialik, Sophy Goren, Valeria Asato, Ortal Ariel-Cohen, Arava Reizis, Alexandra Dorman, Carla W G Hoitink, Janny Westdijk, Shai Ashkenazi, Philippe Sansonetti, Laurence A Mulard, Armelle Phalipon
The results of a clinical study with an experimental vaccine against Shigella, intestinal bacteria that cause severe diarrhea and dysentery. The paper was authored by a team of researchers and clinicians at Tel Aviv University, Tel Aviv Sourasky Medical Center, Institut Pasteur, Ariel University and Intravacc. The clinical study in healthy adults shows that the vaccine is well tolerated and immunogenic. Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release. For more information, see also our press release
ACS Central Science
17th March, 2021
Robert M F van der Put, Carolien Smitsman, Alex de Haan, Martin Hamzink, Hans Timmermans, Joost Uittenbogaard, Janny Westdijk, Michiel Stork, Olga Ophorst, Françoise Thouron, Catherine Guerreiro, Philippe J Sansonetti Armelle Phalipon, Laurence A Mulard
Vaccines
1st December, 2020
Thomas J. M. Michiels, Wichard Tilstra, Martin R J Hamzink, Justin W de Ridder, Maarten Danial, Hugo D Meiring, Gideon F A Kersten, Wim Jiskoot, Bernard Metz
Deze website maakt gebruik van cookies zodat we u de best mogelijke gebruikerservaring kunnen bieden. Cookie-informatie wordt opgeslagen in uw browser en voert functies uit zoals u herkennen wanneer u terugkeert naar onze website en ons team helpen begrijpen welke delen van de website u het meest interessant en nuttig vindt.
Strikt noodzakelijke cookies moeten te allen tijde zijn ingeschakeld, zodat we uw voorkeuren voor cookie-instellingen kunnen opslaan.
Als u deze cookie uitschakelt, kunnen we uw voorkeuren niet opslaan. Dit betekent dat u elke keer dat u deze website bezoekt, cookies opnieuw moet in- of uitschakelen.